January 08, 2025 07:54 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Sheesh Mahal row: AAP leaders who were denied entry into CM's residence turn towards PM's house | Anna University sexual assault accused is a DMK supporter, not member: MK Stalin | Ajit Doval, Raja Dato discuss bilateral cooperation during India-Malaysia Security Dialogue | US President-elect Donald Trump threatens to use economic force to make Canada 51st US State, Justin Trudeau retorts sharply | Elon Musk raises concern on 'world population decline' including that of India, China | Indian-origin Anita Ananda might replace Justin Trudeau as Canadian PM | 'I won't bite': Kamala Harris tells Senator's husband as he refuses to shake hands with her | Centre announces memorial for Pranab Mukherjee, his daughter thanks PM Modi for 'gracious gesture' | Delhi assembly elections on Feb 5, results on Feb 8 | Allu Arjun visits boy injured during Pushpa 2 stampede in Hyderabad
Sputnik V
Wallpaper Cave

Argentine scientists say one dose of Russia's Sputnik V develops high immune response

| @indiablooms | Apr 14, 2021, at 02:38 pm

Moscow/Sputnik: The Russian COVID-19 vaccine Sputnik V prompts a high immune response even with a single dose, a study by Argentine scientists and cited by the country's government on Tuesday, has shown.

Last month, the Argentine government decided to delay second doses of vaccines in a bid to offset the shortages in drugs against the COVID-19 disease across the world.

"A global analysis of the immune response induced by the Sputnik V vaccine, in which 288 individuals participated, indicates that 94% showed the presence of specific antibodies after receiving a single dose," the government said, citing the study.

Notably, 61 participants were previously infected with COVID-19. According to the study, they had 4.6 times more antibodies after the Russian vaccine shot than the rest of the group.

The study also revealed that 96 percent of people under 60 developed antibodies within 21 days after getting vaccinated. The rate stands at 89 percent among those aged over 60.
After two doses of Sputnik V, 100 percent of immunized people have antibodies, the study also noted.

Sputnik V has so far been approved for use in 60 states across the world. According to phase 3 trial results published in The Lancet medical journal, the vaccine has 91.6 percent efficacy against symptomatic COVID-19.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.